JNJ · News · 20261104N

Orthopedics Separation

JOHNSON & JOHNSON · 2026-11-04 · Importance 50 · Surprise 42 · In source text

Smith+Nephew confirmed that discussions with Johnson & Johnson’s DePuy Synthes unit about combining their orthopedics businesses had ended. The talks reportedly concerned a transaction that could have valued J&J’s unit at up to $22 billion, with disagreements over leadership of the combined group cited as the reason they collapsed. J&J had previously announced plans to spin off its orthopedics business, while reports had suggested a potential $20 billion sale to Apollo Equity Management.

Key facts

• Smith+Nephew's merger talks with Johnson & Johnson's orthopedics unit collapsed; the discussions would have valued Johnson & Johnson's unit at up to $22 billion and ended due to disagreements over leadership of the combined group. source
• Reports suggested a potential $20 billion sale of Johnson & Johnson's orthopedics business to Apollo Equity Management. source
• Smith+Nephew confirmed unsuccessful discussions with Johnson & Johnson's DePuy Synthes unit about a potential combination of their orthopedics businesses. source
• Discussions between Smith+Nephew and Johnson & Johnson's DePuy Synthes unit about combining their orthopedics businesses have ended. source
• Smith+Nephew confirmed that merger discussions with Johnson & Johnson's orthopedics business have ended; the reported reason was disagreements over leadership. source
• Johnson & Johnson had previously announced plans to spin off its orthopedics business. source

Impact estimates